David Sarfati-Mizrahi

Universidad Autónoma de la Ciudad de México

Also affiliated with Universidad Mexicana

MedicineSocial SciencesBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico”.

Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico

npj Vaccines(2023)10.1038/s41541-023-00662-6

N/A

1.1DataRank · unranked

47 citations

Martha Torres, Luis Enrique Soto-Ramírez, Juan J. Calva, Patricio Santillán‐Doherty, Dora Eugenia Carranza-Salazar +28 more

Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico

medRxiv(2022)10.1101/2022.02.08.22270676

N/A

1.1DataRank · unranked

26 citations

Martha Torres, Luis Enrique Soto-Ramírez, Juan J. Calva, Patricio Santillán‐Doherty, Dora Eugenia Carranza-Salazar +28 more